https://www.theragnostics.no/en/author/hilde-str%C3%B8mme/ Hilde Strømme Hugo Blox Builder (https://hugoblox.com)en-usThu, 01 Apr 2021 00:00:00 +0000 https://www.theragnostics.no/media/icon_hu14557955862192370321.png https://www.theragnostics.no/en/author/hilde-str%C3%B8mme/ https://www.theragnostics.no/en/publications/seierstad-2021-sup-18-supf-fluciclovine/ Thu, 01 Apr 2021 00:00:00 +0000 https://www.theragnostics.no/en/publications/seierstad-2021-sup-18-supf-fluciclovine/ <hr> <p>The PET tracer ¹⁸F-fluciclovine (Axumin) was recently approved in the United States and Europe for men with suspected prostate cancer recurrence following prior treatment. This article summarizes studies where systematic sector-based histopathology was used as reference standard to assess the diagnostic accuracy of the tracer ¹⁸F-fluciclovine PET in patients with prostate cancer.</p> https://www.theragnostics.no/en/publications/hernes-2021-prostate-specific/ Thu, 01 Apr 2021 00:00:00 +0000 https://www.theragnostics.no/en/publications/hernes-2021-prostate-specific/ <hr> <p>Prostate-specific membrane antigen PET is a promising diagnostic tool in prostate cancer. The gold standard for the detection of prostate tumor and lymph node metastases is histopathology. The aim of the present review was to investigate accuracy measures of ⁶⁸Ga/¹⁸F-labeled prostate-specific membrane antigen PET tracers in primary and recurrent prostate cancer with systematic sector-based histopathology as the reference standard. A systematic literature search was performed and 34 studies were included. Overall, prostate-specific membrane antigen PET showed high specificity, but variable sensitivity to localize known prostate cancer and detect pelvic lymph node metastases.</p>